A Phase 2 interventional study of PA21 and PA21 in Chronic Kidney Disease Requiring Hemodialysis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.
Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2012, is one of 11 in phase 2, and was the 16th registered.
173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.
Browse Hyperphosphatemia studies →3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Taisho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 183 is above the median of 101 across 143 interventional studies indexed under Hyperphosphatemia.
Median enrollment 117 across the 36 interventional studies, 762 across the 4 observational. Of the 36 that completed or were terminated, 5 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 41 have an industry lead sponsor. The 9 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 5 studies filed under Hyperphosphatemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperphosphatemia with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548840Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2026-11-30 |
| NCT07285291Phase 3Taisho Pharmaceutical Co., Ltd.A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders | 2026-12-22 |
| NCT07548853Phase 3Taisho Pharmaceutical Co., Ltd.A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis | 2027-05-31 |
| NCT07285304Phase 3Taisho Pharmaceutical Co., Ltd.A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Hyperphosphatemia with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: PA21
Drug: PA21
Drug: PA21
Drug: PA21
Drug: Placebo
Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment.
Changes in serum phosphorus concentrations from baseline to the end of treatment were adjusted by serum phosphorus concentration at baseline.
Time frame: 6 weeks
Change From Baseline in Serum Calcium Concentrations.
Time frame: 6 weeks
Change From Baseline in Serum Intact-PTH Concentrations.
Time frame: 6 weeks
| Milestone | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| Started | 39 | 36 | 35 | 36 | 37 |
| Completed | 37 | 31 | 23 | 15 | 30 |
| Not completed | 2 | 5 | 12 | 21 | 7 |
| Withdrew: Adverse event | 1 | 2 | 9 | 6 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Decrease in serum phosphate | 0 | 2 | 3 | 12 | 0 |
| Withdrew: Decrease in serum calcium | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 2 |
Changes in serum phosphorus concentrations from baseline to the end of treatment were adjusted by serum phosphorus concentration at baseline.
| mg/dL | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment. | -1.84 (-2.23 to -1.44) | -2.59 (-3.01 to -2.17) | -3.17 (-3.60 to -2.74) | -3.78 (-4.20 to -3.36) | 0.14 (-0.26 to 0.55) |
| mg/dL | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Serum Calcium Concentrations. | 0.20 ± 0.34 | 0.16 ± 0.33 | 0.38 ± 0.44 | 0.38 ± 0.39 | -0.09 ± 0.31 |
| pg/mL | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Serum Intact-PTH Concentrations. | -35.2 ± 89.8 | -45.6 ± 79.2 | -97.0 ± 92.7 | -86.5 ± 104.0 | 21.5 ± 82.5 |
Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PA21 750 mg/Day | 0/39 (0%) | 1/39 (2.6%) | 13/39 (33.3%) |
| PA21 1500 mg/Day | 0/36 (0%) | 2/36 (5.6%) | 11/36 (30.6%) |
| PA21 2250 mg/Day | 0/35 (0%) | 2/35 (5.7%) | 19/35 (54.3%) |
| PA21 3000 mg/Day | 0/36 (0%) | 1/36 (2.8%) | 20/36 (55.6%) |
| Placebo | 0/37 (0%) | 1/37 (2.7%) | 11/37 (29.7%) |
| Event | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| Brain stem infarctionNervous system disorders | 0/39 | 0/36 | 1/35 | 0/36 | 0/37 |
| Intracranial aneurysmNervous system disorders | 0/39 | 0/36 | 1/35 | 0/36 | 0/37 |
| Liver abscessInfections and infestations | 0/39 | 1/36 | 0/35 | 0/36 | 0/37 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/39 | 1/36 | 0/35 | 0/36 | 0/37 |
| Angina pectorisCardiac disorders | 0/39 | 0/36 | 0/35 | 1/36 | 0/37 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/39 | 0/36 | 0/35 | 0/36 | 1/37 |
| Cerebral infarctionNervous system disorders | 1/39 | 0/36 | 0/35 | 0/36 | 0/37 |
| Cardiac failure congestiveCardiac disorders | 1/39 | 0/36 | 0/35 | 0/36 | 0/37 |
| Event | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/39 | 6/36 | 13/35 | 15/36 | 7/37 |
| NasopharyngitisInfections and infestations | 5/39 | 5/36 | 3/35 | 3/36 | 4/37 |
| ContusionInjury, poisoning and procedural complications | 0/39 | 0/36 | 0/35 | 4/36 | 0/37 |
| ConstipationGastrointestinal disorders | 0/39 | 1/36 | 2/35 | 2/36 | 1/37 |
| HaemorrhoidsGastrointestinal disorders | 0/39 | 0/36 | 2/35 | 0/36 | 0/37 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/39 | 1/36 | 2/35 | 0/36 | 0/37 |
| Abdominal painGastrointestinal disorders | 0/39 | 0/36 | 0/35 | 2/36 | 0/37 |
| FlatulenceGastrointestinal disorders | 0/39 | 0/36 | 0/35 | 1/36 | 2/37 |
| InsomniaPsychiatric disorders | 2/39 | 0/36 | 0/35 | 0/36 | 0/37 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 2/39 | 0/36 | 0/35 | 0/36 | 0/37 |
Total of 5 patients were excluded from analysis because they failed to have primary endpoint.
| Age, Continuous(years) | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 59.4 ± 10.4 | 63.8 ± 12.0 | 61.9 ± 10.5 | 61.4 ± 11.2 | 60.8 ± 10.2 | 61.4 ± 10.9 |
| Sex: Female, Male(Participants) | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 12 | 10 | 15 | 14 | 63 |
| Male | 27 | 23 | 23 | 19 | 23 | 115 |
| Race (NIH/OMB)(Participants) | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 39 | 35 | 33 | 34 | 37 | 178 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Dialysis vintage(months) | PA21 750 mg/Day | PA21 1500 mg/Day | PA21 2250 mg/Day | PA21 3000 mg/Day | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 77.6 ± 67.5 | 85.1 ± 60.7 | 95.8 ± 81.9 | 91.5 ± 58.6 | 71.0 ± 45.0 | 83.7 ± 63.5 |
Ran from Jan 2012 to primary completion in Jul 2012, 5 months.
Results were first posted in Aug 2018, 6 years 1 month after primary completion.
Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PA21
Kissei Pharmaceutical Co., Ltd. →